Evidence map›Paper›PMID 38830930›Full record

ArticleScientific reports2024

Use of Viscous medium to study anthelmintic drug action in Caenorhabditis elegans.

Jacqueline R Hellinga, Jürgen Krücken, Hinrich Schulenburg, Georg von Samson-Himmelstjerna

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jacqueline R HellingaInstitute für Parasitologie und Tropenveterinärmedizin, Freie Universität Berlin, Robert von Ostertag Str. 7, 14163, Berlin, Germany.
Jürgen KrückenInstitute für Parasitologie und Tropenveterinärmedizin, Freie Universität Berlin, Robert von Ostertag Str. 7, 14163, Berlin, Germany.
Hinrich SchulenburgZoologisches Institut, Christian-Albrechts-Universität Zu Kiel, Am Botanischen Garten 1-9, 24118, Kiel, Germany.
Georg von Samson-HimmelstjernaInstitute für Parasitologie und Tropenveterinärmedizin, Freie Universität Berlin, Robert von Ostertag Str. 7, 14163, Berlin, Germany. samson.georg@fu-berlin.de.

Funding

Collaborative Research Center CRC 1182 project A1.1Volkswagen Foundation,Germany 96693
6 · The paper itself

Abstract

Caenorhabditis elegans is an appealing tool for experimental evolution and for working with antiparasitic drugs, from understanding the molecular mechanisms of drug action and resistance to uncover new drug targets. We present a new methodology for studying the impact of antiparasitic drugs in C. elegans. Viscous medium was initially designed for C. elegans maintenance during long-term evolution experiments. Viscous medium provides a less structured environment than the standard nematode growth media agar, yet the bacteria food source remains suspended. Further, the Viscous medium offers the worm population enough support to move freely, mate, and reproduce at a rate comparable to standard agar cultures. Here, the Viscous medium was adapted for use in antiparasitic research. We observed a similar sensitivity of C. elegans to anthelmintic drugs as in standard liquid media and statistical difference to the standard agar media through a larval development assay. Using Viscous medium in C. elegans studies will considerably improve antiparasitic resistance research, and this medium could be used in studies aimed at understanding long-term multigenerational drug activity.

Indexed as

AnthelminticsCaenorhabditis elegansCulture MediaAgarAnimalsDrug ResistanceLarvaViscosityAgarAnthelminticsCulture MediaAnthelminticsCaenorhabditis elegansLarval developmentViscous medium

Identifiers

PMID38830930
PMCPMC11148144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.